| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/22/2004 | US20040143131 in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates |
| 07/22/2004 | US20040143117 serine/threonine kinase inhibitors; 2,3-diphenylquinoxalines in which at least one of the phenyls is substituted with an amine group, particularly 2-[4-(2-aminoprop-2-yl)phenyl]-3-phenylquinoxaline; treating cancer |
| 07/22/2004 | US20040143115 e.g., 1-[2-Benzoxazol-2-ylaminomethyl)-piperidin-1-yl]-1-(2-methyl-5phenyl-thiazol4-yl)-methanone; used to treat disorders where an antagonist of a human orexin receptor is required |
| 07/22/2004 | US20040143114 useful for synthesis of non-natural oligonucleotide analogues which exhibit excellent anti-sense or anti-gene activity and in vivo stability |
| 07/22/2004 | US20040143112 Immunomodulatory oligonucleotides |
| 07/22/2004 | US20040143025 Carbon monoxide generating compunds for treatment of vascular, inflammatory and immune disorders |
| 07/22/2004 | US20040143022 Amine compounds and inhibiting neurotransmitter reuptake |
| 07/22/2004 | US20040143021 Administering modafinil; side effect reduction |
| 07/22/2004 | US20040143020 Psychological and central nervous system disorders |
| 07/22/2004 | US20040143019 Sustained release suppositories; for chelate therapy |
| 07/22/2004 | US20040143017 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| 07/22/2004 | US20040143015 Mixture of antidiabetic agents and carrier; prevent, delay metabolism disorders |
| 07/22/2004 | US20040143014 Therapeutic use of alpha-2-delta ligands |
| 07/22/2004 | US20040143013 Use of docosahexaenoic acid and arachidonic acid enhancing the growth of preterm infants |
| 07/22/2004 | US20040143012 Retinoids; bioavailability; mouth administering |
| 07/22/2004 | US20040143010 Synergistic mixture with phosphodiesterase inhibitor; control concentration of cyclic guanosine monophosphate in penis |
| 07/22/2004 | US20040143008 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 07/22/2004 | US20040143006 Peroxisome proliferator activator; antidiabetic agents; insulin resistance; |
| 07/22/2004 | US20040143005 Colon cleansing compositions and methods |
| 07/22/2004 | US20040143004 Metronomic dosing of taxanes |
| 07/22/2004 | US20040143003 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 07/22/2004 | US20040143002 Amorphous form of 3-[2-(dimethylamino) ethyl]-N-methyl-1H-indole-5-methane sulfonamide succinate (sumatriptan succinate) |
| 07/22/2004 | US20040143000 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds |
| 07/22/2004 | US20040142999 Novel compounds and compositions as cathepsin inhibitors |
| 07/22/2004 | US20040142994 bronchitis; chronic obstructive pulmonary disease; rhinitis; antihistamines; antiallergens; antipyretics |
| 07/22/2004 | US20040142993 Viricides |
| 07/22/2004 | US20040142992 Method of treating tremors |
| 07/22/2004 | US20040142990 Concentrating epothilone in culture; complexing; antiproliferative agents |
| 07/22/2004 | US20040142989 Viricides |
| 07/22/2004 | US20040142988 Bladder diseases; bone diosrders; central nerevous system diosrders |
| 07/22/2004 | US20040142987 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists |
| 07/22/2004 | US20040142986 Controlling transforming growth facor; artificial skin; wound healing agents |
| 07/22/2004 | US20040142983 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| 07/22/2004 | US20040142982 Urea derivatives as integrin alpha 4 antagonists |
| 07/22/2004 | US20040142978 Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2 |
| 07/22/2004 | US20040142976 Modulation cytokine sensitive diseases, cellular adhesion molecules; Aids therapy; antihistamines; antiarthritic agents; bone disorders; malaria; cachexia; Crohn's disease |
| 07/22/2004 | US20040142973 Method of treatment of prostate cancer and composition for treatment thereof |
| 07/22/2004 | US20040142972 Sleep disorders; side effect reduction ; antihistamine antagonist |
| 07/22/2004 | US20040142971 Benzothiophene compounds having antiinfective activity |
| 07/22/2004 | US20040142970 Treatment of hyperkinetic movement disorder with donepezil |
| 07/22/2004 | US20040142968 Premenstrual tension; irritable bowel disorders; administering local anesthetic; injected as nontoxic gel or oral capsule |
| 07/22/2004 | US20040142967 Pain maintenance |
| 07/22/2004 | US20040142966 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 07/22/2004 | US20040142965 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| 07/22/2004 | US20040142964 Novel compounds |
| 07/22/2004 | US20040142963 Cardiovascular disorders |
| 07/22/2004 | US20040142962 Attention defect disorders; alcoholism; drug abuse; Parkinson's disease; anxiolytic agents; antidepressants |
| 07/22/2004 | US20040142961 Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations |
| 07/22/2004 | US20040142960 Yohimbine as immunobiologically active agent |
| 07/22/2004 | US20040142959 Method of treatment |
| 07/22/2004 | US20040142958 Combination therapy for the treatment of pain |
| 07/22/2004 | US20040142957 Bactericides; photostability, waterproofing |
| 07/22/2004 | US20040142956 Piperidine derivatives |
| 07/22/2004 | US20040142954 Antiinflammatory agents; antihistamines; Alzheimer's disease; anticholesterol agents; cardiovascular disorders; inflammatory bowel disorders; antitumor agents; antidiabetic agents; brain disorders; multiple sclerosis |
| 07/22/2004 | US20040142953 Inhibitors of histone deacetylase |
| 07/22/2004 | US20040142951 3H-quinazolin-4-one derivatives as MAO-B inhibitors |
| 07/22/2004 | US20040142947 Pyrrolopyrimidines |
| 07/22/2004 | US20040142945 Antiarthritic agents; multiple sclerosis ; organ rejection ; antidiabetic agents; inflammatory bowel disorders; antiischemic agents; skin disorders |
| 07/22/2004 | US20040142944 Compositions for nasal application |
| 07/22/2004 | US20040142941 Therapeutic compounds |
| 07/22/2004 | US20040142938 for treating diabetes and related diseases |
| 07/22/2004 | US20040142937 disorders such as Huntington's Chorea, Parkinson's disease, Alzheimer's disease and other memory disorders, vascular dementia, multi-infarct dementia, Lewy body dementia, or neurogenerative dementia |
| 07/22/2004 | US20040142936 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
| 07/22/2004 | US20040142935 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor liqands and/or serotonergic ligands |
| 07/22/2004 | US20040142934 treatment of rheumatoid arthritis and/or pain; INHIBIT activity of VEGF receptor tyrosine kinase and VEGF-dependent cell proliferation |
| 07/22/2004 | US20040142932 treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase activity |
| 07/22/2004 | US20040142931 inhibit the tyrosine kinase activity of growth factor receptors such as HER1, HER2, and HER4 |
| 07/22/2004 | US20040142929 due to hyperreflexive detrusor activity and urgency incontinence |
| 07/22/2004 | US20040142928 particularly against herpes viruses |
| 07/22/2004 | US20040142927 Inhibitors of p38 |
| 07/22/2004 | US20040142925 Piperazine derivatives their preparation and uses in therapy |
| 07/22/2004 | US20040142923 inhibitors of urotensin II |
| 07/22/2004 | US20040142922 Benzodioxole derivatives |
| 07/22/2004 | US20040142921 treatment and/or prevention of type 2 diabetes and associated metabolic syndrome |
| 07/22/2004 | US20040142920 acute or chronic transplant rejection or inflammatory or autoimmune diseases |
| 07/22/2004 | US20040142919 Benzazepinone alpha vintegrin receptor antagonists |
| 07/22/2004 | US20040142918 Method of inhibiting adhesion formation |
| 07/22/2004 | US20040142917 Porphyrin derivatives |
| 07/22/2004 | US20040142915 11beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer |
| 07/22/2004 | US20040142914 Extended transdermal contraceptive regimens |
| 07/22/2004 | US20040142913 Method and kit for reducing the symptoms of peripheral vascular disease |
| 07/22/2004 | US20040142912 Treatment of systemic lupus erythematosis |
| 07/22/2004 | US20040142911 acetone, a salicylate-based compound, an emollient and one or more terpenes and essential oils; treating pain associated with cancer |
| 07/22/2004 | US20040142910 inhibiting elastase and/or collagenase in a wound, including contacting the wound with a composition including a combination of a sulfonated styrene copolymer and a tetracycline, especially doxycycline |
| 07/22/2004 | US20040142908 Cytoprotection by means of phosphotyrosine |
| 07/22/2004 | US20040142907 for the preventive or curative treatment of hepatocellular deficiency |
| 07/22/2004 | US20040142906 Conpositions and method to prevent and treat brain and spinal cord injuries |
| 07/22/2004 | US20040142905 Washing the Central Nervous System tissue by repeatedly flushing a neuroprotective medicament composition consisting of a pre-emulsion solution of at least one emulsifier in oil and an active ingredient know to suppress cerebrospinal fluid |
| 07/22/2004 | US20040142904 Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| 07/22/2004 | US20040142903 micronized fenofibrate in combination with cyclodextrin, a metal docusate or lauryl sulfate and a water insoluble dispersable carrier |
| 07/22/2004 | US20040142902 cholesterol lowering agent provided parenterally in a sustained release dosage form, e.g., as an injected matrix or stored within a drug delivery device; fewer side effects; reduces compliance problems with oral dosage |
| 07/22/2004 | US20040142900 polypeptide with the transport function of herpesviral VP22 protein and which can regulate cell cycle progression, e.g. proteins which can induce apoptosis, or proteins which can arrest cells from the cell cycle to arrest cell proliferation |
| 07/22/2004 | US20040142892 expression cassettes comprising a eukaryotic promoter and a first RNA polymerase promoter operably linked to a nucleic acid encoding a secretable RNA polymerase comprising a RNA polymerase and a secretion domain, and internal ribosome entry site |
| 07/22/2004 | US20040142888 Modulators of RabGGT and methods of use thereof |
| 07/22/2004 | US20040142886 use of vascular endothelial growth factor to enhance smooth muscle cell proliferation and to treat diseases associated with reduced smooth muscle cell proliferation |
| 07/22/2004 | US20040142883 prolonged serum half-life to permit treatment regimens of about once every 5-7 days or longer, while retaining antibacterial properties in vivo |
| 07/22/2004 | US20040142882 Use of glycyrrhizin and its derivatives as RANTES inducers |
| 07/22/2004 | US20040142881 sulfofucosylacylglycerol derivatives |
| 07/22/2004 | US20040142879 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
| 07/22/2004 | US20040142877 Ligands of the $g(a)v$g(b)6 integrin |